- Home
- / Sumitomo Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Stock Price
¥802
2023-03-24
Market Capitalization
¥318.6 B
2023-03-24
Revenue
¥560 B
FY, 2022
CreditSafe score
?
Score changed on Mar 27, 2023
Premium Content
Learn moreFinancial statements
| JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|
| Revenue | 466.8B | 459.3B | 482.7B | 516.0B | 560.0B |
| Cost of goods sold | 106.0B | 107.4B | 123.6B | 131.8B | 150.5B |
| Gross profit | 360.8B | 351.8B | 360.2B | 384.9B | 411.7B |
| Gross profit margin, % | 77.3% | 76.6% | 74.6% | 74.6% | 73.5% |
| Operating expense total | 264.0B | 274.9B | 260.0B | 307.9B | 313.3B |
| Depreciation and amortization | 12.9B | 14.0B | 17.4B | 22.7B | 38.3B |
| EBITDA | 96.8B | 76.9B | 100.3B | 77.0B | 98.3B |
| EBITDA margin, % | 20.7% | 16.7% | 20.8% | 14.9% | 17.6% |
| EBIT | 78.6B | 57.4B | 82.2B | 71.2B | 60.2B |
| EBIT margin, % | 16.8% | 12.5% | 17.0% | 13.8% | 10.8% |
| Interest income | 1.2B | 2.5B | 2.4B | 234.0M | 255.0M |
| Interest expense | 394.0M | 178.0M | 699.0M | 2.6B | 3.1B |
| Pre tax profit | 84.9B | 65.0B | 83.9B | 77.9B | 83.0B |
| Income tax expense | 31.4B | 16.4B | 48.0B | 41.0B | 42.4B |
| Net Income | 53.4B | 48.6B | 35.9B | 36.8B | 40.6B |
Footer menu
Products
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension